VEGF-targeted therapy: Therapeutic potential and recent advances

Oncologist

Volumn 10, Issue 6, 2005, Pages 382-391

  Rosen, Lee S ^a,b  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Angiogenesis; Bevacizumab; Breast cancer; Colorectal cancer; Lung cancer; PTK787; Vascular endothelial growth factor; Vatalanib; VEGF

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; COMBRETASTATIN A4 PHOSPHATE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; N ACETYLCOLCHINOL PHOSPHATE; OXALIPLATIN; PACLITAXEL; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; ATAXIA; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DYSPNEA; ENDOTHELIUM CELL; FATIGUE; HUMAN; HYPERTENSION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RASH; REVIEW; SOLID TUMOR; THROMBOEMBOLISM; TUMOR GROWTH; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; EDUCATION, MEDICAL, CONTINUING; FEMALE; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 22244452376     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-6-382     Document Type: Review

References (53)

1. Miller KD. Recent translational research: antiangiogenic therapy for breast cancer-where do we stand? Breast Cancer Res 2004;6:128-132.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
3. Dvorak HF, Brown LF, Detmar M et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-1039.
4. Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002;9(2 suppl):36-44.
5. Underiner TL, Ruggeri B, Gingrich DE. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem 2004;11:731-745.
6. Betsholtz C, Karlsson L, Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays 2001;23:494-507.
7. Reinmuth N, Liu W, Jung YD et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J 2001;15:1239-1241.
8. Hsu S, Huang F, Friedman E. Platelet-derived growth factor-B increases colon cancer cell growth in vivo by a paracrine effect. J Cell Physiol 1995;165:239-245.
9. Ishikawa F, Miyazono K, Hellman U et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989;338:557-562.
10. Kitadai Y, Ellis LM, Tucker SL et al. Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Pathol 1996;149:1541-1551.
11. Bergsland E. Angiogenesis inhibitors in combination with chemotherapy. Presented at the Translational and Therapeutic Advances in Colorectal Cancer meeting, New York, October 28-30, 2004.
12. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
13. Iqbal S, Lenz HJ. Angiogenesis inhibitors in the treatment of colorectal cancer. Semin Oncol 2004;31(suppl 17):10-16.
14. Warren RS, Yuan H, Matli MR et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-1797.
15. Borgstrom P, Gold DP, Hillan KJ et al. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999; 19:4203-4214.
16. Thomas AL, Morgan B, Drevs J et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ ZK 222584. Semin Oncol 2003;30(suppl 6):32-38.
17. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337.
18. Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-4655.
19. Iyer S, Chaplin DJ, Rosenthal DS et al. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 1998;58:4510-4514.
20. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002;99:2060-2069.
21. Goto H, Yano S, Zhang H et al. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 2002;62:3711-3715.
22. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
23. Kabbinavar FF, Schulz J, McCleod M et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11. Proc Am Soc Clin Oncol 2004;23:249.
24. Fernando N. Advances with bevacizumab. Presented at the Translational and Therapeutic Advances in Colorectal Cancer meeting, New York, October 28-30, 2004.
25. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
26. Hurwitz H, Fehrenbacher L, Cartwright T et al. Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab. Proc Am Soc Clin Oncol 2004;23:295.
27. Novotny WF, Holmgren E, Nelson B et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) does not increase the incidence of venous thromboembolism when added to first-line chemotherapy to treat metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004;23:252.
28. Mass R. Genentech BioOncology Pipeline and Development Plans: Presented at the Translational and Therapeutic Advances in Colorectal Cancer meeting, New York, October 28-30, 2004.
29. Giantonio B, Catalano P, Meropol N et al. The addition of bevacizumab (anti-VEGF) to FOLFOX4 in previously treated advanced colorectal cancer (advCRC): an updated interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Presented at the 2004 Gastrointestinal Cancers Symposium: Current Status and Future Directions for Prevention and Management, San Francisco, CA, January 22-24, 2004. Available at http://www.asco.org/ac/ 1,1003,_12-002636-00_18_0027-00_19-00554,00.asp. Accessed December 7, 2004.
30. Bevacizumab combined with oxaliplatin-based chemotherapy prolongs survival for previously treated patients with advanced colorectal cancer [press release]. National Cancer Institute. National Institutes of Health (NIH) News. Available at http://www.ecog.org/general/E3200_NIH_RELEASE.PDF. Accessed December 7, 2004.
31. Steward WP, Thomas A, Morgan B et al. Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004;23:259.
32. Drevs J, Mross K, Medinger M et al. Phase I dose-escalation and pharmacokinetic (PK) study of the VEGF inhibitor PTK787/ZK222584 (PTK/ZK) in patients with liver metastases. Proc Am Soc Clin Oncol 2003;22:284.
33. Trarbach T, Schleucher N, Riedel U et al. Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK 222584 (PTK/ZK) in combination with irinotecan/5-fluorouracil/leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003;22:285.
34. Atiqur Rahman M, Toi M. Anti-angiogenic therapy in breast cancer. Biomed Pharmacother 2003;57:463-470.
35. Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887.
36. Uzzan B, Nicolas P, Cucherat M et al. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004;64:2941-2955.
37. Cobleigh MA, Langmuir VK, Sledge GW et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(suppl 16):117-124.
38. Miller KD, Rugo HS, Cobleigh MA et al. Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 2002;76:S37.
39. Swain S. A pilot study to evaluate angiogenesis after treatment with bevacizumab in previously untreated patients with inflammatory breast cancer. Presented at the 7th Annual Targeted Therapies for the Treatment of Breast Cancer Investigators' Meeting, Beaver Creek, CO, July 14-17, 2004.
40. Petit AM, Rak J, Hung MC et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-1530.
41. Konecny GE, Meng YG, Untch M et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10:1706-1716.
42. Klein P. Targeting VEGF & the HER family. Presented at the 7th Annual Targeted Therapies for the Treatment of Breast Cancer Investigators' Meeting, Beaver Creek, CO, July 14-17, 2004.
43. Dickler M, Rugo H, Caravelli J et al. Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol. 2004; 23:127.
44. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June, 2004. Presentation slides available at http://www.asco.org/ac/ 1,1003,_ 12-002511-00_ 18-0026-00_19-009196,00.asp. Accessed November 18, 2004.
45. Delmotte P, Martin B, Paesmans M et al. [VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis]. Rev Mal Respir 2002;19:577-584.
46. Meert AP, Paesmans M, Martin B et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2002;87:694-701.
47. Koukourakis MI, Giatromanolaki A, Thorpe PE et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 2000;60:3088-3095.
48. Masuya D, Huang C, Liu D et al. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer 2001;92:2628-2638.
49. Tanaka F, Ishikawa S, Yanagihara K et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 2002;62:7124-7129.
50. O'Byrne KJ, Koukourakis MI, Giatromanolaki A et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000;82:1427-1432.
51. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
52. Rugo HS, Herbst RS, Liu G et al. Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2004;23:163.
53. Heymach J, Dong R, Dimery I et al. ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: results of the run-in phase of a two-part, randomized phase II study. Proc Am Soc Clin Oncol 2004;22:207.